BR112014000792A2 - compostos de piperidinila para uso como inibidores da tanquirase - Google Patents

compostos de piperidinila para uso como inibidores da tanquirase

Info

Publication number
BR112014000792A2
BR112014000792A2 BR112014000792A BR112014000792A BR112014000792A2 BR 112014000792 A2 BR112014000792 A2 BR 112014000792A2 BR 112014000792 A BR112014000792 A BR 112014000792A BR 112014000792 A BR112014000792 A BR 112014000792A BR 112014000792 A2 BR112014000792 A2 BR 112014000792A2
Authority
BR
Brazil
Prior art keywords
inhibitors
compounds
formula
tanquirase
present
Prior art date
Application number
BR112014000792A
Other languages
English (en)
Inventor
Toure Bakary-Barry
Hiu-Tung Chen Christine
Fan Jianne
V Dipietro Lucian
G Palermo Mark
David Shultz Michael
Chin Chin Noel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112014000792A2 publication Critical patent/BR112014000792A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

abstract the present invention provides for compounds of formula (i): (i) wherein r1- r4 and n are defined herein. the present invention also provides for pharmaceutical compositions and combinations comprising a compound of formula (i) as well as for the use of such compounds as tankyrase inhibitors and in the treatment of wnt signaling and tankyrase 1 and 2 signaling related disorders which include, but are not limited to, cancer. tradução: resumo patente de invenção: "compostos de piperidinila para uso como inibidores da tanquirase". a presente invenção fornece compostos de fórmula (i). a presente invenção também fornece composições farmacêuticas e combinações compreendendo um composto de fórmula (i) assim como o uso de tais compostos como inibidores da tanquirase e no tratamento da sinalização wnt e tanquirase 1 e 2 que sinaliza os distúrbios relacionados que incluem, mas não são limitados a este, câncer.
BR112014000792A 2011-07-13 2012-07-13 compostos de piperidinila para uso como inibidores da tanquirase BR112014000792A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161507321P 2011-07-13 2011-07-13
PCT/IB2012/053613 WO2013008217A1 (en) 2011-07-13 2012-07-13 4 - piperidinyl compounds for use as tankyrase inhibitors

Publications (1)

Publication Number Publication Date
BR112014000792A2 true BR112014000792A2 (pt) 2017-10-31

Family

ID=46604017

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014000792A BR112014000792A2 (pt) 2011-07-13 2012-07-13 compostos de piperidinila para uso como inibidores da tanquirase

Country Status (20)

Country Link
US (2) US9163003B2 (pt)
EP (1) EP2731940B1 (pt)
JP (1) JP5957077B2 (pt)
KR (1) KR20140051944A (pt)
CN (1) CN103797006B (pt)
AP (1) AP2014007400A0 (pt)
AU (1) AU2012282076A1 (pt)
BR (1) BR112014000792A2 (pt)
CA (1) CA2841932A1 (pt)
CO (1) CO6880065A2 (pt)
CR (1) CR20140071A (pt)
DO (1) DOP2014000012A (pt)
EA (1) EA201490272A1 (pt)
ES (1) ES2548513T3 (pt)
IL (1) IL230430A0 (pt)
MA (1) MA35342B1 (pt)
MX (1) MX2014000536A (pt)
TN (1) TN2014000016A1 (pt)
WO (1) WO2013008217A1 (pt)
ZA (1) ZA201400374B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013012723A1 (en) * 2011-07-13 2013-01-24 Novartis Ag Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors
ES2611504T3 (es) 2012-03-07 2017-05-09 Institute Of Cancer Research: Royal Cancer Hospital (The) Compuestos de isoquinolin-1-ona 3-aril-5-sustituida y sus usos terapéuticos
AU2014239542A1 (en) * 2013-03-15 2015-10-01 Araxes Pharma Llc Covalent inhibitors of KRas G12C
PL3030554T3 (pl) * 2013-08-07 2018-07-31 Merck Patent Gmbh Piperydynowe pochodne mocznikowe
DK3044221T3 (en) 2013-09-11 2018-04-23 Institute Of Cancer Res Royal Cancer Hospital The 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ON COMPOUNDS AND THERAPEUTIC APPLICATION THEREOF
WO2015135461A1 (zh) * 2014-03-10 2015-09-17 四川海思科制药有限公司 取代的二氢苯并呋喃-哌啶-甲酮衍生物、其制备及用途
AU2015258100B2 (en) 2014-05-07 2019-05-16 Merck Patent Gmbh Heterocyclyl-butanamide derivatives
WO2016006974A2 (en) * 2014-07-11 2016-01-14 St Pharm Co., Ltd. Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
WO2016006975A2 (en) * 2014-07-11 2016-01-14 St Pharm Co., Ltd. Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
KR101739003B1 (ko) 2014-07-11 2017-05-23 에스티팜 주식회사 신규한 트리아졸로피리미디논 또는 트리아졸로피리디논 유도체, 및 이들의 용도
KR20160007347A (ko) 2014-07-11 2016-01-20 에스티팜 주식회사 신규한 이미다조트리아지논 또는 이미다조피라지논 유도체, 및 이들의 용도
RU2018119935A (ru) * 2015-11-02 2019-12-04 Мерк Патент Гмбх 1,4-дикарбонилпиперидильные производные
KR101777475B1 (ko) * 2015-12-08 2017-09-11 에스티팜 주식회사 신규한 디히드로피라노피리미디논 유도체 및 이들의 용도
WO2017112777A1 (en) 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
MA49458A (fr) 2017-06-21 2020-04-29 SHY Therapeutics LLC Composés interagissant avec la superfamille ras destinés à être utilisés dans le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladies fibrotiques
AU2019392502A1 (en) 2018-12-03 2021-07-22 Merck Patent Gmbh 4-heteroarylcarbonyl-N-(phenyl or heteroaryl) piperidine-1-carboxamides as inhibitors of tankyrases
EP4013749A1 (en) * 2019-08-15 2022-06-22 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
WO2022146614A1 (en) * 2020-12-03 2022-07-07 Washington University Methods of treating and preventing kidney disease

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
WO2000042025A1 (fr) 1999-01-14 2000-07-20 Meiji Seika Kaisha, Ltd. Inhibiteurs de poly(adp-ribose) polymerase consistant en des derives de pyrimidine
US6710058B2 (en) * 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
DE10056312A1 (de) 2000-11-14 2002-05-16 Bayer Ag Substituierte Amidoalkyluracile und ihre Verwendung
AUPR201600A0 (en) * 2000-12-11 2001-01-11 Fujisawa Pharmaceutical Co., Ltd. Quinazolinone derivative
JPWO2002094790A1 (ja) 2001-05-23 2004-09-09 三菱ウェルファーマ株式会社 縮合ヘテロ環化合物およびその医薬用途
DE60231439D1 (de) 2001-12-06 2009-04-16 Merck & Co Inc Mitotische kinesinhemmer
DE10201240A1 (de) 2002-01-15 2003-07-24 Bayer Ag Substituierte Alkyluracile und ihre Verwendung
AUPS019702A0 (en) 2002-01-29 2002-02-21 Fujisawa Pharmaceutical Co., Ltd. Condensed heterocyclic compounds
WO2003070707A1 (fr) 2002-02-19 2003-08-28 Ono Pharmaceutical Co., Ltd. Composes condenses derives de la pyridazine et medicaments contenant lesdits composes comme ingredients actifs
AUPS137402A0 (en) 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US7183287B2 (en) 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
DE602004022819D1 (de) 2003-06-06 2009-10-08 Vertex Pharma Von atp-bindende kassette transportern
CL2004002050A1 (es) 2003-08-13 2005-06-03 Pharmacia Corp Sa Organizada B Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
US7439254B2 (en) 2003-12-08 2008-10-21 Cytokinetics, Inc. Compounds, compositions, and methods
GB0405101D0 (en) * 2004-03-06 2004-04-07 Astrazeneca Ab Compounds
US7375102B2 (en) 2004-06-28 2008-05-20 Amgen Sf, Llc Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use
EP1763518B1 (en) * 2004-06-30 2012-01-11 Janssen Pharmaceutica NV Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
KR20190072678A (ko) 2004-09-02 2019-06-25 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
AU2006261715A1 (en) 2005-06-27 2007-01-04 Amgen Inc. Anti-inflammatory aryl nitrile compounds
EP2021337B1 (en) * 2006-04-25 2010-01-13 Eli Lilly And Company Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
US8466150B2 (en) 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
CN101939006B (zh) 2007-09-12 2015-09-16 吉宁特有限公司 磷酸肌醇3-激酶抑制剂化合物与化疗剂的联合以及使用方法
CN101909631B (zh) 2007-10-25 2012-09-12 健泰科生物技术公司 制备噻吩并嘧啶化合物的方法
KR20100089869A (ko) 2007-11-05 2010-08-12 노파르티스 아게 Ｗｎｔ 활성화의 측정 및 ｗｎｔ-관련 암의 치료를 위한 방법 및 조성물
KR101179753B1 (ko) 2007-11-06 2012-09-04 제일약품주식회사 신규한 트리시클릭 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 포함하는 약학조성물
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
ES2529545T3 (es) 2008-03-27 2015-02-23 Janssen Pharmaceutica, N.V. Tetrahidrofenantridinonas y tetrahidrociclopentaquinolinonas como inhibidores de la polimerización de tubulina y PARP
WO2013012723A1 (en) * 2011-07-13 2013-01-24 Novartis Ag Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors

Also Published As

Publication number Publication date
MA35342B1 (fr) 2014-08-01
ZA201400374B (en) 2014-10-29
ES2548513T3 (es) 2015-10-19
TN2014000016A1 (en) 2015-07-01
MX2014000536A (es) 2014-12-05
USRE46942E1 (en) 2018-07-10
US20150126513A1 (en) 2015-05-07
KR20140051944A (ko) 2014-05-02
JP2014522855A (ja) 2014-09-08
WO2013008217A1 (en) 2013-01-17
CN103797006B (zh) 2016-01-27
EA201490272A1 (ru) 2014-05-30
CR20140071A (es) 2014-10-16
AU2012282076A1 (en) 2014-02-27
EP2731940B1 (en) 2015-08-19
CA2841932A1 (en) 2013-01-17
JP5957077B2 (ja) 2016-07-27
CO6880065A2 (es) 2014-02-28
AP2014007400A0 (en) 2014-01-31
IL230430A0 (en) 2014-03-31
CN103797006A (zh) 2014-05-14
NZ620426A (en) 2015-08-28
EP2731940A1 (en) 2014-05-21
DOP2014000012A (es) 2014-07-31
US9163003B2 (en) 2015-10-20

Similar Documents

Publication Publication Date Title
BR112014000792A2 (pt) compostos de piperidinila para uso como inibidores da tanquirase
CY1120866T1 (el) Παρεμποδιστες dna-pk
CL2017002650A1 (es) Compuestos novedosos
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
CR20150633A (es) Derivados del bipirazol como inhibidores jak
CL2012001821A1 (es) Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CU20110168A7 (es) Derivados de benzofuranilo
PE20151423A1 (es) Derivados tetrahidropiranilo inhibidores del hcv
MD20150043A2 (ro) Inhibitori ai histon-demetilazelor
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
UY33241A (es) ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
EA201300211A1 (ru) N-ацилсульфонамидные промоторы апоптоза
BR112015001502A2 (pt) derivados de tipo azaindazol ou diazaindazol para tratamento de dor
UY33246A (es) Tienopirimidinas que contienen cicloalquilo para composiciones farmacéuticas
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
BR112015019412A2 (pt) inibidores de bace1
CO6341625A2 (es) Derivados de indol como agentes anticáncer
UY33723A (es) ?COMPUESTOS Y SU USO PARA TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON Aß?.
UY32154A (es) Derivados de isoquinolinona, procesos para su preparacion, composiciones farmaceuticas que los contiene y su uso en terapia
NI201200162A (es) Inhibidores de pirazolil quinoxalina cinasa
UA110793C2 (uk) Піразолілхіноксалінові інгібітори кінази
CY1114207T1 (el) Παραγωγα βενζοφουρανυλιου για χρηση ως αναστολεις γλυκοκινασης

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: REFERENTE A RPI NO 2424 DE 20/06/2017, POR TER SIDO INDEVIDO.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2475 DE 12/06/2018